FDA Approves DARZALEX FASPRO® for Newly Diagnosed Multiple Myeloma Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4h ago
0mins
Source: PRnewswire
- Significant Efficacy Improvement: The D-VRd regimen achieved a 52.3% MRD-negativity rate in newly diagnosed multiple myeloma patients, significantly higher than VRd's 34.8%, indicating its potential as a new standard of care.
- Extended Survival Rates: In a median follow-up of 39 months, the proportion of patients achieving sustained MRD-negativity nearly doubled to 42.6%, suggesting potential extensions in progression-free and overall survival for patients.
- FDA Approval Milestone: This approval marks the twelfth indication for DARZALEX FASPRO®, reinforcing its foundational role in treating both newly diagnosed and relapsed/refractory multiple myeloma patients, representing a significant advancement in treatment options.
- Clinical Research Validation: The CEPHEUS study demonstrated the safety and efficacy of the D-VRd regimen in 395 patients, significantly reducing the risk of disease progression or death by 40% compared to traditional therapies, thereby enhancing patient confidence in treatment outcomes.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 221.490
Low
190.00
Averages
218.50
High
240.00
Current: 221.490
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
